Human Recombinant Insulin Market

1
Human Recombinant Insulin Market
Due to the mounting incidence of diabetes and the
rising need for human insulin analogues, the
global human recombinant insulin market is
growing at a significant rate. Due to advanced
expertise and ability to manufacture continuous
insulin delivery during the day, the industry
has seen strong demand for long-acting human
insulin in the coming years. By Product, the
market is categorized into rapid-acting,
long-acting, short-acting, premixed, and
intermediate-acting. Long-acting human insulin
segment is expected to grow at the fastest rate
in the market due to advanced competence and
capability to pose constant insulin delivery
during the day. By Brand, the market is
subdivided into Humalog, Lantus, Novolog,
Novorapid, Apidra, Humulin, Novolin, Levemir and
others. The Lantus accounted the foremost share
in the human recombinant insulin market. In
addition, Levemir and Apidra are expected to grow
at fastest rate in the market. By Distribution
channel, the market is subdivided into hospital
pharmacies, online pharmacies and retail
pharmacies. The retail pharmacies accounted the
largest share in the human recombinant insulin
market, as it offers extensive range of diabetic
products including over-the-counter and
prescription drugs for the diabetic patients. By
application, the market is subdivided into type I
diabetes and type II diabetes. The type II
diabetes accounted the largest share in the human
recombinant insulin market due to mounting
incidence of type II diabetes. The key growth
drivers for the human recombinant insulin market
are increasing the number of diabetic patients,
promising medical reimbursement in developing
countries, increasing risk factors contributing
to diabetes, increasing the market supply of
generic human insulin drugs and increasing the
demand for human insulin analogues. The growth of
the human recombinant insulin market is also
encouraged by the anticipated patent expiry of
major human analogue products, an expanding
geriatric population, mounting RD for drug
discovery production and technical innovation
in human insulin delivery systems. Recent
News In August 2018, Novo Nordisk A/S acquired
Ziylo, to accelerate development of glucose
responsive insulin for therapeutic and diagnostic
applications. Competitive Insights Novo Nordisk
A/S, Biocon Limited, Sanofi S.A., Wanbang
Biopharmaceuticals Co., Ltd., Bioton S.A., Eli
Lilly and Company, Zhuhai United Laboratories
Co., Ltd., Julphar Gulf Pharmaceutical
Industries, Dongbao Enterprise Group Co., Ltd,
and Gan Lee Pharmaceuticals, Ltd. are the key
players offering human recombinant insulin
products.
2
VynZ Research Call 91-996-028-8381 Toll-Free
(U.S. and Canada) 1-888-253-3960 Email
enquiry_at_vynzresearch.com Web https//www.vynzrese
arch.com Connect with Us LinkedIn Facebook
Twitter